6,759 Shares in Mylan NV (MYL) Purchased by Caxton Associates LP
Caxton Associates LP acquired a new position in Mylan NV (NASDAQ:MYL) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 6,759 shares of the company’s stock, valued at approximately $247,000.
Several other large investors have also modified their holdings of the business. Pzena Investment Management LLC grew its stake in shares of Mylan by 2.6% in the 3rd quarter. Pzena Investment Management LLC now owns 21,657,877 shares of the company’s stock worth $792,678,000 after buying an additional 542,725 shares in the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Mylan by 8.7% in the 3rd quarter. Bank of New York Mellon Corp now owns 10,226,277 shares of the company’s stock worth $374,280,000 after acquiring an additional 818,059 shares during the last quarter. FMR LLC lifted its holdings in shares of Mylan by 1.9% in the 2nd quarter. FMR LLC now owns 9,171,840 shares of the company’s stock worth $331,470,000 after acquiring an additional 168,347 shares during the last quarter. Menora Mivtachim Holdings LTD. lifted its holdings in shares of Mylan by 2.7% in the 3rd quarter. Menora Mivtachim Holdings LTD. now owns 7,224,654 shares of the company’s stock worth $264,422,000 after acquiring an additional 191,250 shares during the last quarter. Finally, Dimensional Fund Advisors LP lifted its holdings in shares of Mylan by 8.8% in the 3rd quarter. Dimensional Fund Advisors LP now owns 5,582,182 shares of the company’s stock worth $204,329,000 after acquiring an additional 449,752 shares during the last quarter. 82.16% of the stock is owned by institutional investors and hedge funds.
Several equities research analysts have recently issued reports on the stock. ValuEngine lowered shares of Mylan from a “sell” rating to a “strong sell” rating in a report on Wednesday, November 21st. Cantor Fitzgerald restated a “hold” rating and issued a $41.00 target price on shares of Mylan in a report on Tuesday, November 20th. Argus upgraded shares of Mylan from a “hold” rating to a “buy” rating and set a $42.00 target price for the company in a report on Thursday, November 15th. JPMorgan Chase & Co. set a $45.00 target price on shares of Mylan and gave the stock a “buy” rating in a report on Tuesday, November 6th. Finally, Wells Fargo & Co upgraded shares of Mylan from a “market perform” rating to a “buy” rating and set a $40.00 target price for the company in a report on Tuesday, November 6th. Two analysts have rated the stock with a sell rating, five have given a hold rating and fourteen have issued a buy rating to the company. Mylan has an average rating of “Buy” and an average price target of $46.56.
Mylan (NASDAQ:MYL) last announced its quarterly earnings data on Monday, November 5th. The company reported $1.25 earnings per share for the quarter, beating analysts’ consensus estimates of $1.19 by $0.06. Mylan had a net margin of 4.71% and a return on equity of 19.39%. The company had revenue of $2.86 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter last year, the business posted $1.10 EPS. The firm’s revenue for the quarter was down 4.2% on a year-over-year basis. Research analysts forecast that Mylan NV will post 4.66 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “6,759 Shares in Mylan NV (MYL) Purchased by Caxton Associates LP” was first published by Daily Political and is the sole property of of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of US and international copyright & trademark laws. The correct version of this news story can be accessed at https://www.dailypolitical.com/2018/12/18/6759-shares-in-mylan-nv-myl-purchased-by-caxton-associates-lp.html.
Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, brand name, and over-the-counter (OTC) products worldwide. The company operates through three segments: North America, Europe, and Rest of World. It offers pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, nebulized, and cream or ointment forms.
Recommended Story: Day Trading – Risk Worth the Reward?
Want to see what other hedge funds are holding MYL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Mylan NV (NASDAQ:MYL).
Receive News & Ratings for Mylan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan and related companies with MarketBeat.com's FREE daily email newsletter.